GNCA Stock Crashes 97.4% on April 30, 2026 After Bankruptcy

GNCA stock has become one of the worst performers on NASDAQ, trading at just $0.0001 per share on April 30, 2026. The biotech company’s stock has collapsed nearly 97.4% from its previous close of $0.0039, reflecting the severe financial distress facing Genocea Biosciences, Inc. The Cambridge, Massachusetts-based cancer immunotherapy developer filed for Chapter 11 bankruptcy reorganization in July 2022, a move that fundamentally changed the company’s trajectory. Today’s intraday trading shows minimal volume at 30,268 shares, well below the 80,568-share average. This represents one of the most dramatic declines in the healthcare sector, with GNCA stock now trading near penny stock levels after reaching a 52-week high of $1.45.

What Happened to GNCA Stock Today

GNCA stock experienced a devastating intraday decline, losing $0.0038 per share in a single session. The stock opened at $0.0007 and fell to its current floor of $0.0001, representing a 97.4% daily loss. Trading volume dropped to just 37.6% of average, indicating minimal investor interest at these depressed levels.

The company’s market capitalization has effectively collapsed to zero, making it nearly impossible to raise capital through equity offerings. Year-to-date performance shows GNCA stock down 99.99% from its 52-week high of $1.45, demonstrating the complete erosion of shareholder value. Track GNCA on Meyka for real-time updates on this distressed biotech name.

Financial Metrics Show Severe Distress

Genocea Biosciences faces catastrophic financial metrics that explain the stock’s collapse. The company reports negative earnings per share of -$0.2249 and negative free cash flow of -$0.7096 per share, indicating ongoing cash burn with no revenue generation.

Key financial ratios paint a bleak picture. The price-to-book ratio stands at 0.00025, while the company’s net profit margin is -9.4%. Operating margins are deeply negative at -31.7%, showing the company burns cash on research and development spending of 23.8% of revenue. Despite these challenges, the current ratio of 2.24 suggests the company maintains some liquidity, though this provides limited comfort given the bankruptcy status.

Cancer Immunotherapy Pipeline Status

Genocea Biosciences developed two main cancer immunotherapy candidates before its financial collapse. GEN-011, an adoptive T cell therapy, remains in Phase 1/2a clinical trials for solid tumors. GEN-009, a neoantigen vaccine candidate, also progresses through Phase 1/2a trials using the company’s proprietary ATLAS discovery platform.

The ATLAS platform profiles each patient’s CD4+ and CD8+ T cell immune responses to tumor antigens identified through next-generation sequencing. However, the bankruptcy filing has severely limited the company’s ability to fund clinical development. With 740 full-time employees at the time of the filing, the company has likely undergone significant restructuring. The lack of recent earnings announcements and minimal trading activity suggest the pipeline has stalled.

Market Sentiment and Trading Activity

Trading activity in GNCA stock remains extremely thin, with volume at just 30,268 shares representing only 37.6% of the 80,568-share daily average. The bid-ask spread has likely widened significantly given the penny stock status and bankruptcy proceedings. Intraday trading shows no meaningful price discovery, as the stock trades at the absolute floor of $0.0001.

Liquidation pressure continues as bankruptcy proceedings advance. The company’s enterprise value sits at negative $26.01 million, indicating liabilities exceed assets. Meyka AI rates GNCA with a grade of C+, reflecting the distressed fundamentals and bankruptcy status. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

Final Thoughts

GNCA stock collapsed 97.4% following Genocea Biosciences’ July 2022 bankruptcy filing, now trading at penny stock levels with minimal market value and negative cash flow. The company’s cancer immunotherapy programs remain stalled in early-stage trials with insufficient funding. Investors face near-total loss risk as bankruptcy proceedings continue. This case illustrates the significant risks of biotech investing and the difficulty of funding clinical development in competitive oncology markets.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.